Transcript Slide 1

Development of National
Guidelines for Immunoglobulin
Therapy
M. ELIZABETH M. YOUNGER CRNP, PH.D
THE JOHNS HOPKINS UNIVERSITY
BALTIMORE, MARYLAND
Disclosures
 CSL Behring: Consultant and Research Support
 RMS: Clinical Advisory Panel
 Immune Deficiency Foundation: Chair, Nurse
Advisory Committee
Immunoglobulin Replacement Therapy
The Standard of Care
for treatment of those immunodeficiencies
characterized by hypogammaglobulinemia and
impaired antibody responses to antigenic stimuli
Immunodeficiencies requiring Ig replacement
 Primary Immunodeficiencies:
 Common variable immunodeficiency
 Agammaglobulinemia (X-linked or autosomal recessive)
 Severe combined immunodeficiency (pre-transplant and post
transplant until humoral immune reconstitution occurs)
 Hyper IgM deficiency
 Secondary immunodeficiencies
 Agammaglobulinemia secondary to monoclonal antibody
therapy (e.g. rituximab)
 Hypogammaglobulinemia secondary to CLL
Goal of Therapy
To deliver therapy safely and effectively
To achieve this goal: therapy should be
facilitated by professionals who have
been educated regarding the rationale
for therapy and its administration
Considerations
 Site of care




Home
Hospital
Infusion Suite
Medical Office
 Mode of Administration

Intravenous
Peripheral Line
 Central Venous Line


Subcutaneous
Pump
 Push


Facilitated subcutaneous
More Considerations
 Administered by
 Physician
 Nurse Practitioner
 Registered Nurse
 Vocational Nurse
 Patient
 Other trained lay person
And Still More
 Intravenous Infusions
 Frequency: every 2-4 weeks
 Product (excipients, stabilizers)
 Product Concentration (5, 6, 10%)
 Rate of Infusion
 Pre-medications (?)
 Patient risk factors/co-morbidities
Still More…
 Subcutaneous Infusions
 Frequency: Daily to every 4 weeks
 Product Concentration (10, 16 or 20%)
 Number of Sites (1 to ……)
 Time of Infusion (rapid push to hours)
 Premedication?
Process
Guidelines were developed to achieve the goal for
therapy while taking into account all the
considerations
Process
 Literature review
 Explore regional variations
 Evidence based practice
 Draft guidelines
 Circulate guidelines
 Come together to reach
consensus
Beth Younger, Kris Epland, Amy Meyer, Maggie Dodds, Carla Duff,
Deb Sedlak, William Blouin, Jeanette Scott, Loris Aro